

To: Kathryn Guyton[GuytonK@iarc.fr]; Isabelle Baldi[Isabelle.Baldi@isped.u-bordeaux2.fr]; Blair, Aaron (NIH/NCI) [V][blaira@exchange.nih.gov]; GMC24@columbia.edu[GMC24@columbia.edu]; Egeghy, Peter[Egeghy.Peter@epa.gov]; Forastiere, Francesco[f.forastiere@deplazio.it]; Lin Fritschi[lin.fritschi@curtin.edu.au]; Jahnke, Gloria (NIH/NIEHS) [E][jahnke@niehs.nih.gov]; Bill Jameson[]; frank lecurieux[frank.lecurieux@echa.europa.eu]; Martin, Matt[Martin.Matt@epa.gov]; John McLaughlin[John.McLaughlin@oahpp.ca]; Teresa Rodriguez[]; Matthew Ross[MRoss@cvm.msstate.edu]; Rusyn, Ivan[I.Rusyn@cvm.tamu.edu]; Consolato Sergi[biotechlab@gmail.com]; Mannetje, Andrea[A.Mannetje@massey.ac.nz]; Lauren Zeise[]; Christopher Portier[]
Cc: imo-pro@iarc.fr[imo-pro@iarc.fr]
From: Kromhout, J. (Hans)
Sent: Mon 3/16/2015 6:48:50 AM
Subject: RE: IARC Monograph vol 112- Lancet oncology article draft
TLO vol 112 13 March 2015+HK.docx

Hi Kathryn,

The write up looks pretty good. In the attachment my comments in track changes in the word document. I missed a few lines (short paragraph) on the issues we wrote up on exposure assessment and the multiple exposure situations all epi-studies have to deal with. I think it would be good to have that in the Lancet Oncology as well.

Best and good luck with the submission, Hans

From: Kathryn Guyton [GuytonK@iarc.fr]
Sent: Friday, March 13, 2015 3:35 PM
To: Isabelle Baldi; Blair, Aaron (NIH/NCI) [V]; GMC24@columbia.edu; Egeghy, Peter; Forastiere, Francesco; Lin Fritschi; Jahnke, Gloria (NIH/NIEHS) [E]; Bill Jameson; Kromhout, J. (Hans); frank lecurieux; Matt Martin; John McLaughlin; Teresa Rodriguez; Matthew Ross; Rusyn, Ivan; Consolato Sergi; Mannetje, Andrea; Lauren Zeise; Christopher Portier
Cc: imo-pro@iarc.fr
Subject: IARC Monograph vol 112- Lancet oncology article draft

Dear all,

We thank you again for your outstanding contributions to the IARC Monograph volume 112 meeting!

We provide for your review and comment no later than Monday COB in your time zone a draft of the Lancet Oncology article. We ask for your feedback using track changes, preferably using the google doc sent separately or in the appended Word file. Please turn on track changes before entering any suggested edits. We strongly prefer direct edits to the text but will attempt to address any comments as well.

Please be reminded that the information summarised herein is strictly embargoed until the Lancet Oncology article is published online. We will be pleased to inform you when this has occurred.

My very best regards,
With thanks to you all,
Kate
Kate Z. Guyton PhD DABT
Responsible Officer, Volume 112
Monographs Section
International Agency for Research on Cancer
150, cours Albert Thomas
69372 Lyon Cedex 08

France
Tel: [+33] (0)4 72 73 86 54
Guytonk@iarc.fr<mailto:Guytonk@iarc.fr>